Germany Crispr And Cas Genes Market Size & Outlook
Germany crispr and cas genes market, 2018-2030 (US$M)
Related Markets
Germany crispr and cas genes market highlights
- The Germany crispr and cas genes market generated a revenue of USD 315.8 million in 2024 and is expected to reach USD 786.6 million by 2030.
- The Germany market is expected to grow at a CAGR of 16.7% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 315.8 million |
| Market revenue in 2030 | USD 786.6 million |
| Growth rate | 16.7% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, Germany accounted for 6.7% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 688.9 million by 2030.
Product was the largest segment with a revenue share of 89.93% in 2024. Horizon Databook has segmented the Germany crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for a substantial revenue share in Europe’s CRISPR and Cas gene market. It has several institutes and universities that are actively involved in the adoption of CRISPR techniques to serve their research purposes, thereby, boosting revenue generation in this country.
In March 2020, researchers from German universities, namely the Martin Luther University Halle-Wittenberg and the Science of Pathogens, developed a Cas9 variant that is designed to increase the specificity of CRISPR technology. Such studies are anticipated to optimize CRISPR-Cas9 technology in this region.
Merck KGaA is one of the prominent players in this region. Besides, strategic initiatives undertaken by other players are expected to drive the country’s market growth over the forecast period. In November 2017, CRISPR Therapeutics, along with Casebia Therapeutics, collaborated with the German biopharmaceutical company CureVac AG.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany crispr and cas genes market size, by product & service, 2018-2030 (US$M)
Germany CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
